ערך בספרים למניה: Cassava Sciences, Inc. (SAVA)
Cassava Sciences, Inc. (SAVA) is developing a breakthrough protein correction method for Alzheimer's, leveraging patent protection for its molecules despite regulatory challenges. The bps trend reflects the actual net asset base, where the value 1.70 represents the current metric. Final approval of Simufilam will grant the company absolute pricing power due to the highly inelastic demand for the therapy.
cassavasciences.com - פילוחים אנליטיים ומדדי מפתח (SAVA)
Book value per share determines the portion of equity attributable to a single security after deducting all liabilities from total assets. By analyzing the capital level per share, an investor assesses the financial resilience of Cassava Sciences, Inc. (SAVA) regarding costly clinical trials for Alzheimer's drugs, where maintaining a significant reserve is critical for overcoming regulatory barriers and minimizing the risks of failure.